1. Marabotto, et al. Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data. Clinical and Experimental Gastroenterology, 2020;13: 99–104
2. Putra B P, Miftahussurur M. Vonoprazan-based therapy has lower failure rate in eradicating helicobacter pylori compared to proton pump inhibitors-based therapy: a meta-analysis of randomized controlled trials. The New Armenian Medical Journal, 2019;13(4):22-30
4. Shinozaki S, et al. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis. Digestion, 2021;102:319–325
10. Mims. Vonoprazan. 2022. https://www.mims.com/indonesia/drug/info/vonoprazan?mtype=generic
13. FDA. Drugs@FDA: FDA-Approved Drugs. 2021. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215152
16. MIMS. Vocinti. 2021. https://www.mims.com/malaysia/drug/info/vocinti?type=full
17. FDA. Highlights of prescibing information Voquezna. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215152s000,215153s000lbl.pdf
20. Miwa H, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers – results from two phase 3, non‐inferiority randomised controlled trials. Aliment Pharmacol Ther. 2017 Jan; 45(2): 240–252.
21. Yasuhiko G, et al. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease. Medicine, 2020;99(11) - p e19520
25. Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther 2017; 46:106.